Atlas Venture Fund XI, L.P.

CIK 1708269 · last filed 2024-11-05

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$117.44M

Companies

5

Total Filings

52

Lifetime Open-Market Net

$9.69M

Filer Profile

Reported Address
400 TECHNOLOGY SQUARE
10TH FLOOR
CAMBRIDGE, MA 02139
Phone
(857) 201-2700
State of Incorporation
DE
Related Filers
Atlas Venture Associates XI, L.P. — 21 joint filings, latest 2025-02-10
Atlas Venture Associates XI, LLC — 21 joint filings, latest 2025-02-10
Atlas Venture Opportunity Fund I, L.P. — 20 joint filings, latest 2024-02-28
Atlas Venture Associates Opportunity I, L.P. — 18 joint filings, latest 2024-02-28
Atlas Venture Associates Opportunity I, LLC — 18 joint filings, latest 2024-02-28
Atlas Venture Opportunity Fund II, L.P. — 7 joint filings, latest 2025-02-10
Atlas Venture Associates Opportunity II, LLC — 6 joint filings, latest 2025-02-10
ATLAS VENTURE ASSOCIATES X, L.P. — 3 joint filings, latest 2021-05-26
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Third Harmonic Bio, Inc. (THRD) Delisted 10%+ Owner 9,798,075 $5.38 $52.71M $0 1 2024-11-05
Day One Biopharmaceuticals, Inc. (DAWN) Delisted 10%+ Owner 6,008,534 $21.53 $129.36M $0 3 2022-12-14
ImageneBio, Inc. (IKNA) Delisted 10%+ Owner 176,877 $17.16 $3.04M $9.69M 1 2021-12-14
DYN 10%+ Owner 7,326,117 $16.03 $117.44M $0 1 2021-07-15
Akero Therapeutics, Inc. (AKRO) Delisted 10%+ Owner 2,706,412 $54.65 $147.91M $0 1 2020-01-02

Recent Filings · Page 2 of 6

52 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-07-02 KRRO Notice (144) −85,955 -$1.17M EDGAR
2026-06-29 DYN Notice (144) −102,969 -$2.16M EDGAR
2026-06-26 DYN Notice (144) −162,954 -$3.36M EDGAR
2026-06-25 DYN Notice (144) −12,699 -$258.2K EDGAR
2026-06-24 KRRO Notice (144) −41,345 -$566.8K EDGAR
2026-06-24 DYN Notice (144) −50,530 -$1.02M EDGAR
2026-06-23 DYN Notice (144) −77,855 -$1.62M EDGAR
2026-06-23 KRRO Notice (144) −101,579 -$1.41M EDGAR
2026-06-22 KRRO Notice (144) −21,339 -$277.2K EDGAR
2026-05-06 DYN Notice (144) −43,621 -$762.1K EDGAR
Showing 11–20 of 52
Page 2 of 6
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.